doxapram will be administered intravenously (IV) during spontaneous breathing trial. diaphragmatic excursion will be evaluated by an expert in respiratory muscle ultrasound
Age
20–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial
You may not be if
Refusal Allergy to doxapram neuromuscular disorders inability to evaluate the diaphragm
